Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

被引：54
|
作者：
Post, Frank A. [1 ]
Tebas, Pablo [2 ]
Clarke, Amanda [3 ]
Cotte, Laurent [4 ]
Short, William R. [2 ]
Abram, Michael E. [5 ]
Jiang, Shuping [5 ]
Cheng, Andrew [5 ]
Das, Moupali [5 ]
Fordyce, Marshall W. [5 ]
机构：
[1] Kings Coll Hosp NHS Fdn Trust, Dept Sexual Hlth, London, England
[2] Univ Penn, Perelman Sch Med, Philadelphia, PA USA
[3] Brighton & Sussex Univ Hosp NHS Trust, Dept Sexual Hlth, Brighton, E Sussex, England
[4] Hospices Civils Lyon, Croix Rousse Hosp, Dept Infect Dis, Lyon, France
[5] Gilead Sci Inc, Foster City, CA USA
来源：
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2017年 / 74卷 / 02期
关键词：
tenofovir alafenamide; emtricitabine; chronic kidney disease; bone mineral density; HIV; CHRONIC KIDNEY-DISEASE; DISOPROXIL FUMARATE; DOUBLE-BLIND; ANTIRETROVIRAL THERAPY; NON-INFERIORITY; TENOFOVIR/EMTRICITABINE; EPIDEMIC; COHORT;
D O I：
10.1097/QAI.0000000000001186
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Tenofovir disoproxil fumarate is associated with renal and bone toxicity. In a single-arm, open-label study of 242 virologically suppressed, HIV-infected participants with creatinine clearance 30-69 mL/min who switched to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, participants had stable creatinine clearance, significant and durable improvements in proteinuria, albuminuria, and tubular proteinuria (P < 0.001), and significant increases in hip and spine bone mineral density through 96 weeks (P < 0.001). Eighty-eight percent maintained HIV-1 RNA <50 c/mL at week 96. These longer-term results support the use of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-infected individuals with mild-moderately impaired renal function.
引用
下载
收藏
页码：180 / 184
页数：5
相关论文
共 50 条
  • [21] Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF
    Joseph Gathe
    Jose R. Arribas
    Jan Van Lunzen
    Will Garner
    Rebecca M. Speck
    Randall Bender
    Sanatan Shreay
    Thai Nguyen
    The Patient - Patient-Centered Outcomes Research, 2015, 8 : 445 - 454
  • [22] Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged &gt;65 or older: week 48 results from a phase 3b, open-label trial
    Maggiolo, F.
    Rizzardini, G.
    Molina, J. M.
    Pulido, F.
    DeWit, S.
    Vandekerckhove, L.
    Berenguer, J.
    D'Antoni, M.
    Blair, C.
    Chuck, S.
    Piontkowsky, D.
    Martin, H.
    McNicholl, I.
    Payne, B.
    Gallant, J.
    HIV MEDICINE, 2020, 21 : 17 - 17
  • [23] Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF
    Gathe, Joseph
    Arribas, Jose R.
    Van Lunzen, Jan
    Garner, Will
    Speck, Rebecca M.
    Bender, Randall
    Shreay, Sanatan
    Thai Nguyen
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2015, 8 (05): : 445 - 454
  • [24] Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged&gt;65 or older: week 48 results from a phase 3b, open-label trial
    Maggiolo, F.
    Rizzardini, G.
    Molina, J-M
    Pulido, F.
    De Wit, S.
    Vandekerckhove, L.
    Berenguer, J.
    D'Antoni, M.
    Blair, C.
    Chuck, S.
    Piontkowsky, D.
    Martin, H.
    McNicholl, I.
    Haubrich, R.
    Gallant, J.
    HIV MEDICINE, 2019, 20 : 138 - 138
  • [25] Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
    Franco Maggiolo
    Giuliano Rizzardini
    Jean-Michel Molina
    Federico Pulido
    Stephane De Wit
    Linos Vandekerckhove
    Juan Berenguer
    Michelle L. D’Antoni
    Christiana Blair
    Susan K. Chuck
    David Piontkowsky
    Hal Martin
    Richard Haubrich
    Ian R. McNicholl
    Joel Gallant
    Infectious Diseases and Therapy, 2021, 10 : 775 - 788
  • [26] Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
    Maggiolo, Franco
    Rizzardini, Giuliano
    Molina, Jean-Michel
    Pulido, Federico
    De Wit, Stephane
    Vandekerckhove, Linos
    Berenguer, Juan
    D'Antoni, Michelle L.
    Blair, Christiana
    Chuck, Susan K.
    Piontkowsky, David
    Martin, Hal
    Haubrich, Richard
    McNicholl, Ian R.
    Gallant, Joel
    INFECTIOUS DISEASES AND THERAPY, 2021, 10 (02) : 775 - 788
  • [27] Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults
    Tashima, Karen
    Crofoot, Gordon
    Tomaka, Frank L.
    Kakuda, Thomas N.
    Brochot, Anne
    Vanveggel, Simon
    Opsomer, Magda
    Garner, William
    Margot, Nicolas
    Custodio, Joseph M.
    Fordyce, Marshall W.
    Szwarcberg, Javier
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2014, 17 : 171 - 172
  • [28] Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) in Virally Suppressed Chronic Hepatitis B (CHB) Patients With Renal Impairment: Week 48 Results From a Phase 2 Open-Label Study
    Janssen, Harry
    Heo, Jeong
    Fournier, Claire
    Ahn, Sang Hoon
    Coffin, Carla S.
    Hui, Aric Josun
    Elkhashab, Magdy
    Jafri, Syed-Mohammed
    Mo, Shuyuan
    Winans, Jake
    Flaherty, John
    Gaggar, Anuj
    Chuang, Wan-Long
    Gane, Ed J.
    Lim, Young-Suk
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S530 - S530
  • [29] EFFICACY AND SAFETY OF SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH RENAL IMPAIRMENT: WEEK 24 RESULTS FROM A PHASE 2 OPEN-LABEL STUDY
    Janssen, Harry L. A.
    Lim, Young-Suk
    Gane, Edward J.
    Fournier, Claire
    Ahn, Sang Hoon
    Tsang, Owen
    Chuang, Wan Long
    Heo, Jeong
    Hui, Aric Josun
    Elkhashab, Magdy
    Chen, Chi-Yi
    Su, Wei-Wen
    Flaherty, John F.
    Gaggar, Anuj
    Tan, Susanna
    Lau, Audrey H.
    Suri, Vithika
    Mo, Shuyuan
    Subramanian, Mani
    Jafri, Syed-Mohammed
    Agarwal, Kosh
    Lampertico, Pietro
    Marchesini, Giulo
    Coffin, Carla S.
    Huang, Yi-Hsiang
    HEPATOLOGY, 2019, 70 : 306A - 307A
  • [30] A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naive patients
    Bracchi, Margherita
    Pagani, Nicole
    Dalla Pria, Alessia
    Milinkovic, Ana
    Nwokolo, Nneka
    Thomas, Lervina
    Mandalia, Sundhyia
    Boffito, Marta
    Moyle, Graeme
    HIV RESEARCH & CLINICAL PRACTICE, 2021, 22 (05) : 128 - 139
12345